Alternative approaches, such as eftilagimod alpha, a soluble LAG-3 protein activating antigen-presenting cells (APCs), have shown promise in combination with pembrolizumab, particularly in PD-L1-high NSCLC patients, with 8.3% ORR and 33.3% Disease Control Rate (DCR) [102]. The gene discussed is LAG3; the disease is non-small cell lung carcinoma.